Mitochondria in the etiology and pathogenesis of Parkinson's disease

Annals of Neurology

Volumn 44, Issue 3 SUPPL. 1, 1998, Pages

  Schapira, A H V ^a,b   Gu, M ^a   Taanman, J W ^a   Tabrizi, S J ^a   Seaton, T ^a   Cleeter, M ^a   Cooper, J M ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA;

BRAIN MITOCHONDRION; CONFERENCE PAPER; DYSTONIA; ENZYME DEFICIENCY; GENE MUTATION; GENE TRANSFER; HUMAN; MOLECULAR CLONING; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0031684326     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440714     Document Type: Conference Paper

References (64)

1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science 1983;219:979-980
2. Langston JW, Forno LS, Robert CS, Irwin I. MPTP causes selective damage to the zona compacta of the substantia nigra in the squirrel monkey. Brain Res 1984;292:390-394
3. Forno LS, Langston JW, DeLanney LE, Irwin I. An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 1988;448:150-157
4. Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990;27:276-282
5. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047
6. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet 1995;57: 77-86
7. Schapira AHV, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269
8. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827
9. Janetzky B, Hauck S, Youdim MBH et al. Unaltered aconitase activity but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994;169:126-128
10. Gu M, Owen AD, Toffa SEK, et al. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci 1998 [in press]
11. Mizuno Y, Suzuki K, Ohta S. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 1990;96:49-57
12. Mizuno Y, Matuda S, Yoshino H, Moro H, Hattori N, Ikebe S. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994;35: 201-210
13. +, a metabolite of the neurotoxin MPTP. Life Sci 1985;36:2503-2508
14. 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 1990;55:2142-2145
15. Mann VM, Cooper JM, Daniel SE, Jenner P, Marsden CD, Schapira AHV. Complex I, iron and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881
16. Cooper JM, Daniel SE, Marsden CD, Schapira AHV. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain. Mov Disord 1995;10:295-297
17. Gu M, Gash MT, Cooper JM, et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997; 12:418-422
18. 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease. J Neurol Sci 1994; 125:77-81
19. Penn AMW, Roberts T, Hodder J, Allen PS, Zhu G, Martin WRW. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 1995;45:2097-2099
20. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994;9:125-138
21. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AHV, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992;115: 333-342
22. Haas RH, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol 1995;37:714-722
23. Wooten GF, Currie LJ, Bennett JP, Harrison MB, Trugman JM, Parker WD. Maternal inheritance in Parkinson's disease. Ann Neurol 1997;41:265-268
24. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992;32:782-788
25. Gu M, Cooper JM, Taanman JW, Schapira AHV. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998 [in press]
26. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-503
27. Chomyn A, Martinuzzi A, Yoneda M, et al. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc Natl Acad Sci USA 1992;89:4221-4225
28. Lys mutation causing myoclonic epilepsy and ragged red fibers. Am J Hum Genet 1994;34:966-974
29. Dunbar DR, Moonie PA, Zeviani M, Holt IJ. Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet 1996;5:123-129
30. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-671
31. Swerdlow RH, Parks JK, Wooten GF, Miller SW, Davis RE, Parker WD. As in Parkinson's disease, a bioenergetic defect transfers with mitochondrial DNA of patients with multisystem atrophy [abstract]. Mov Disord 1997;12(Suppl 1):P3
32. Davis RE, Miller S, Herrnstadt C, et al. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 1997;94:4526-4531
33. Tabrizi SJ, Cooper JM, Schapira AHV. Mitochondrial DNA in focal dystonia: a cybrid analysis. Ann Neurol 1998 [in press]
34. Schapira AHV, Warner T, Gash MT, Cleeter MJW, Marinho CFM, Cooper JM. Complex I function in familial and sporadic dystonia. Ann Neurol 1997;41:556-559
35. Przedborski S, Jackson-Lewis V, Muthane U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993;34:715-723
36. Zhang Y, Marcillat O, Giulivi C, Ernster I, Davies KJ. The oxidative inactivaton of mitochondrial electron transport chain components and ATP. J Biol Chem 1990;265:16330-16336
37. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neutotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206
38. + and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J Neurochem 1991;51:1184-1190
39. Cleeter MJW, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992;58:786-789
40. Vingerhoets FJG, Snow BJ, Tetrud JJ, Langston JW, Schulzer M, Calne DB. Positron emission tomogtaphic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol 1994;36:765-770
41. +, in MPTP. In: Markey SP, Castagnoli N, Trevor AJ, Kopin IJ, eds. A neurotoxin producing a parkinsonian syndrome. New York: Academic Press, 1989:571-574
42. +) induces NADH dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 1990;170:1049-1055
43. Chiueh CC, Huang S-J, Murphy DL. Enhanced hydroxyl radical generation by 2′methyl analogue of MPTP: suppression by clorgyline and deovenyl. Synapse 1992;11:346-348
44. Hantraye P, Brouillet E, Ferrante R, et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Med 1996;2:1017-1021
45. Przedborski S, Donaldson D, Murphy PL, et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93:4565-4571
46. Mackenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP toxicity in the common marmoset. Synapse 1997;26:301-306
47. Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagnoli N, Langston JW. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 1997;69:1771-1773
48. Bolaños JP, Almeida A, Stewart V, et al. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J Neurochem 1997;68: 2227-2240
49. Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH. Nitric oxide synthase protein and messenger RNA are discretely localised in neuronal populations of the mammalian CNS together with NAPDH and diaphorase. Neuron 1991;7:615-624
50. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576
51. McNaught KStP, Thull U, Carrupt PA, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1995;50:1903-1911
52. McNaught KStP, Altomare C, Cellamare S, et al. Inhibition of α-ketoglutarate dehydrogenase by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroreport 1995;6:1105-1108
53. Suzuki K, Mizuno Y, Yoshida M. Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity and ATP synthesis by tetrahydroisoquinoline. Neurosci Lett 1988;86:105-108
54. Maruyama W, Dosert W, Naoi M. Dopamine-derived 1-methyl-6,7-dihydroxyisoquinoline as hydroxyl promotors and scavengers: in vivo and in vitro studies. J Neurochem 1995;64: 2635-2643
55. Maruyama W, Dosert W, Matsubara K, Naoi M. N-methyl (R) salsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Rad Biol Med 1995;19:67-75
56. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigtostriatal regions. Neurosci Lett 1988;87:178-182
57. Naoi M, Maruyama W, Dosert P, et al. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl (R) salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioural studies. Brain Res 1966;709:285-295
58. Seaton TA, Cooper JM, Schapira AHV. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 1997;777:110-118
59. Marchetti P, Susin SA, Decaudin D, et al. Apoptosis-associated derangement of mitochondrial function in cells lacking mitochondrial DNA. Cancer Res 1996;56:2033-2038
60. Bernardi P, Broeckemeier KM, Pfeiffer DR. Recent progress on regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 1994;26:509-517
61. Zamzami N, Susin SA, Marchetti P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med 1996;83:1533-1544
62. Prezant TR, Agapian JV, Bohlman C, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndrome deafness. Nature Genet 1993;4:289-294
63. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250
64. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44